“We were extremely impressed by the scientific expertise the management team has built within the organization, and we look forward to helping them expand their product and service offering into adjacent high-growth end markets.” said Noah Rhodes, Managing Director at GPP.
GREENWICH, Conn. and SAN DIEGO (PRWEB)
September 29, 2022
Today Great Point Partners (“GPP”), a Greenwich-based private investment firm focused on the health care industry, announced the growth recapitalization of iXCells Biotechnologies (“iXCells” or the “Company”). iXCells is a high growth provider of products and discovery services to the academic, biotech and pharmaceutical communities worldwide, with a special focus on primary and induced pluripotent stem cell (“iPSC”)-derived cellular models. The Company is led by co-founder & CEO Dr. Lynn Zhang, co-founder & President Dr. Nianwei Lin and co-founder & VP of Finance Dr. Ying Su. iXCells was founded in 2014 by several cell biology experts with the goal of providing best-in-class cell-based products and discovery services. The Company is headquartered in San Diego, California, and has more than 30 employees. “Lynn and Nianwei have done an exceptional job building a rapidly-growing company serving academic, biotech and pharma clients with best-in-class drug discovery solutions and disease-relevant cellular models,” said Noah Rhodes, Managing Director at GPP. “We were extremely impressed by the scientific expertise the management team has built within the organization, and we look forward to helping them expand their product and service offering into adjacent high-growth end markets. ”“Our customers are constantly seeking the highest quality products and services from a provider that partners with them through the drug development process,” said Dr. Lynn Zhang, CEO. “iXCells is uniquely positioned to provide best-in-class services to drug development companies requiring proven quality, white-glove customer service and industry-recognized results.”
About Great Point Partners
Great Point Partners, founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with 30 professionals, investing in the United States, Canada, and Western Europe.
GPP is currently making new minority and majority private equity investments from GPP IV. Great Point manages $1.5B of capital in its private funds and public life sciences equity strategy (BioMedical Value Fund). Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 200 growing health care companies. The private equity funds invest across all sectors of the health care industry with a particular emphasis on biopharmaceutical services and supplies, alternate site care, medical device and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies.
About iXCells
Founded in 2014 and based in San Diego, CA, iXCells Biotechnologies is an innovative cell biology and cell technology company that provides preclinical drug discovery solutions with the focus on disease relevant cellular models enabling technologies and services to the academic, biotech and pharma communities to accelerate the pace of drug discovery. iXCells offers customers access to high quality primary and iPSC derived cells, custom iPSC services, functional bioassay development and drug screening. To learn more about this innovative leader within the preclinical iPSC sector, visit http://www.ixcellsbiotech.com.
Share article on social media or email: